Skip to content

Search

Showing results for "1"

Get involved in ENDIA

ENDIA (Environmental Determinants of Islet Autoimmunity) is a national observational study into the causes of Type 1 Diabetes in childhood.

Teens with diabetes cope with the additional burden of CV protection

ACE inhibitors and statins are well tolerated in teenagers with Type 1 Diabetes but more evidence is required to demonstrate whether they are effective

Diabetes link to deadly diseases

New research led by The Kids' PhD student Matthew Cooper has found that some children with T1D have an increased risk of developing vascular diseases.

Research results

Many of the Centre's researchers have been responsible for discovering and contributing to real game-changers, making a difference to children with diabetes.

ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents

Citation: Libman I, Haynes A, Lyons S, Pradeep P, Rwagasor E, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and

TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in Western Australia

Citation: MacDonald B, Burmaz M, Baker S, et al. TrialR: critical enablers and the need for reusable Rare Disease Clinical Trial infrastructure in

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

Citation: Sek K, Chen AXY, Cole T, Armitage JD, Tong J, ……… Waithman J, Parish IA, et al. Tumor site-directed A1R expression enhances CAR T cell

Realising the potential impact of artificial intelligence for rare diseases – A framework

Rare diseases (RD) are conditions affecting fewer than 1 in 2000 persons, with over 7000 largely genetic RDs affecting 3.5 %-5.9 % of the global population, or approximately 262.9–446.2 million people. The substantial healthcare burden and costs, such as the $1 trillion annual expense in the USA, highlight the urgent need for improved RD management. The International Rare Diseases Research Consortium (IRDiRC) addresses this need through global collaboration, aiming for timely and accurate diagnosis, development of 1000 new therapies, and methodologies to measure impact by 2027.

Congratulations Honours scholarship recipients

The Rio Tinto Children’s Diabetes Centre; A JDRF Global Centre of Excellence (the Centre), announces inaugural Honours Scholarships for students dedicated to type 1 diabetes research.